Piramal has developed a novel process to prepare gliflozins. The new platform technology, which can be applied to any of the gliflozins, involves in-situ reactions with high yields and purity and brings down the cost of manufacturing substantially as compared to prior processes. The in-house IP team has drafted and filed patent applications in the US and India, both of which were granted. The motivation to secure a patent grant was to help in securing market dominance and prevent competitors from using this process of manufacturing. The process would hinder competitors, which became evident when Piramal was faced with a pre-grant opposition in India by a third party (anonymous and represented by an individual, the Opponent). When opposed in such a manner, the patent grant would get blocked as long as the opposition is not overcome, meaning loss of valuable patent term protection (the patent term is for 20 years from the date of application of patent). Download the Case Study to learn more.
